BioLineRx Cash Flow Statement (2023-2025) | BLRX

Cash Flow Statement Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Operating Activities
Net Income -7.93M-8.58M-11.52M-19.50M-3.89M-3.69M-3.76M0.05M-1.97M-2.03M-1.90M
Gains from Sales and Divestitures 27.10M27.10M28.33M31.36M31.36M34.41M34.43M38.10M62.57M71.82M73.43M
Gains from Investment Securities -262.85M
Non-cash Items 4.15M13.01M19.13M-13.41M-25.23M-29.23M-34.65M-7.72M-3.96M-5.08M
Cash from Operations -8.02M-9.68M-9.90M4.99M-14.11M-11.33M-9.82M-8.61M-2.59M-0.18M-2.11M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 0.65M0.43M-0.65M-0.43M
Investing Activities
Capital Expenditures -0.03M-0.07M-0.00M0.22M-0.03M-0.03M0.11M
Change in Acquisitions & Divestments -5.50M-0.51M-7.88M-33.71M-5.79M-12.31M-12.51M-4.21M
Cash from Investing Activities 6.64M11.10M4.10M-20.39M16.69M-8.64M10.18M11.16M-8.18M-3.70M3.67M
Financing Activities
Cash from Financing Activities -0.05M-0.13M3.50M11.74M-0.89M23.88M-1.22M-1.11M9.45M1.60M-0.92M
Additional items
Exchange Rate Effect -0.10M0.44M-0.76M0.19M0.05M-0.27M0.08M0.16M-0.08M0.43M0.07M
Change in Cash -1.42M1.28M-2.31M-3.66M1.68M3.90M-0.87M1.44M-1.32M-2.28M0.65M
Beginning Cash Balance 10.49M8.82M10.03M7.92M4.31M5.72M9.70M9.00M10.35M9.47M7.26M
Free Cash Flow -7.98M-9.62M-9.90M4.78M-14.08M-11.30M-9.82M-8.72M-2.59M-0.18M-2.11M
Net Cash Flow -1.42M1.28M-2.31M-3.66M1.68M3.90M-0.87M1.44M-1.32M-2.28M0.65M